x

Science

Novavax Seeks OK for COVID Vaccine in Needy Countries First

Vaccine maker Novavax announced Thursday it has asked regulators in India, Indonesia and the Philippines to allow emergency use of its COVID-19 vaccine — offering its shot to some low-income countries before rich ones with ample supplies.

U.S.-based Novavax partnered with the Serum Institute of India to apply in the three countries, and plans later this month to also seek the World Health Organization review needed to be part of the COVAX global vaccine program. 

Novavax CEO Stanley Erck called the submissions an "important step toward access to millions of doses of a safe and effective vaccine for countries with an urgent need to control the pandemic."

The company announced it also plans to submit applications in Britain soon, followed by Europe, Australia, Canada and New Zealand, but not in the U.S. until later in the year.

The Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus. That's very different than other widely used vaccines that deliver genetic instructions for the body to make its own spike protein. 

The Novavax shots are easier to store and transport than some other options, and have long been expected to play an important role in increasing supplies in poor countries desperate for more vaccine. 

In June, Novavax announced the vaccine had proved about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the U.S. and Mexico. It also worked against variants circulating in those countries at the time. Side effects were mostly mild.

As for the highly contagious delta variant that now is circulating in much of the world, Novavax also announced Thursday that giving a booster six months after a second shot revved up virus-fighting antibodies that could tackle that mutant. 

Additional studies in Britain and elsewhere are testing if the Novavax shot could be used as a booster after other types of COVID-19 vaccines. Erck said that mix-and-match data might lead to its vaccine becoming "the universal booster of choice" in rich countries.

And the company said Indonesia already had expressed interest in using the Novavax vaccine as a booster following some Chinese-made shots.

The Gaithersburg, Maryland, company said it was on track to produce up to 100 million doses a month by the end of the third quarter and 150 million doses a month by year's end.

RELATED

BANGKOK (AP) — China's Chang'e 6 probe returned on Earth with rock and soil samples from the little-explored far side of the moon in a global first.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

It’s Not as World-Famous as Ramen or Sushi. But the Humble Onigiri is Soul Food in Japan

TOKYO (AP) — The word “onigiri” became part of the Oxford English Dictionary this year, proof that the humble sticky-rice ball and mainstay of Japanese food has entered the global lexicon.

New England is known for its diverse and vibrant food scene.

TIRANA, Albania (AP) — An Albanian appeals court on Tuesday upheld a two-year prison sentence for an elected mayor of the country’s Greek minority, in a move expected to further exacerbate tension with neighboring Greece.

THE HAGUE, Netherlands (AP) — The International Criminal Court said Tuesday it has issued arrest warrants for Russia’s former defense minister and its military chief of staff for attacks on civilian targets in Ukraine, the third time the global court has issued warrants for senior Russian leaders.

FORT PIERCE, Fla. (AP) — Lawyers for Donald Trump on Tuesday will ask the judge presiding over his classified documents case to prevent prosecutors from using evidence seized during an FBI search of his Florida estate and recordings made by one of his former attorneys.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.